Skip to main content
Fig. 8 | BMC Medicine

Fig. 8

From: Combined homologous recombination repair deficiency and immune activation analysis for predicting intensified responses of anthracycline, cyclophosphamide and taxane chemotherapy in triple-negative breast cancer

Fig. 8

The characteristics summary of TNBC patients with HRD and ACT response. TMB, tumour mutation burden; ICIs, immune checkpoint inhibitors; TILs, tumour-infiltrating lymphocytes; NK cells, natural killer cells; TCR/BCR, T cell/B cell receptor; Tfh cells, T follicular helper cells

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us